

Correction

Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential

Marc N. Wein,* Marc Foretz, David E. Fisher, Ramnik J. Xavier, and Henry M. Kronenberg

*Correspondence: mnwein@partners.org (M.N. Wein).
DOI of original article: <https://doi.org/10.1016/j.tem.2018.08.004>
(Trends Endocrinol. Metab. 29, 723–735, 2018)

The authors of this review would like to request that a conflict of interest disclosure be added to their article. Although the article does not suggest any off label drugs, there is discussion about the potential future use of salt-inducible kinase (SIK) inhibitors for skin darkening, which is the topic of a company David E. Fisher co-founded within the past year.

Disclaimer Statement

D.E.F. has a financial interest in Soltego, Inc., a company developing SIK inhibitors for topical skin darkening treatments that might be used for a broad set of human applications. D.E.F.'s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.